Completed PHASE1 INTERVENTIONAL 4-arm NCT03934814

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Sponsor: I-Mab Biopharma US Limited

Conditions Lymphoma Solid Tumor

Interventions Pembrolizumab Rituximab TJ011133

Updated 20 times since 2019 Last updated: Jun 27, 2024 Started: Apr 16, 2019 Primary completion: Jan 10, 2023 Completion: Jan 10, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03934814, this PHASE1 trial focuses on Lymphoma and Solid Tumor and remains completed. Sponsored by I-Mab Biopharma US Limited, it has been updated 20 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

20 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Aug 2024 — Sep 2024 [monthly]

Completed PHASE1
Jul 2024 — Aug 2024 [monthly]

Completed PHASE1
Jun 2024 — Jul 2024 [monthly]

Completed PHASE1
Sep 2023 — Jun 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed

▶ Show 15 earlier versions

Jul 2023 — Sep 2023 [monthly]

Active Not Recruiting PHASE1
Sep 2022 — Jul 2023 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Jan 2022 — Sep 2022 [monthly]

Recruiting PHASE1
Sep 2021 — Jan 2022 [monthly]

Recruiting PHASE1
Jun 2021 — Sep 2021 [monthly]

Recruiting PHASE1
Feb 2021 — Jun 2021 [monthly]

Recruiting PHASE1
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE1
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Oct 2020 — Dec 2020 [monthly]

Recruiting PHASE1
Aug 2020 — Oct 2020 [monthly]

Recruiting PHASE1
Jun 2020 — Aug 2020 [monthly]

Recruiting PHASE1
Mar 2020 — Jun 2020 [monthly]

Recruiting PHASE1
Nov 2019 — Mar 2020 [monthly]

Recruiting PHASE1
Oct 2019 — Nov 2019 [monthly]

Recruiting PHASE1
Jun 2019 — Oct 2019 [monthly]

Recruiting PHASE1

First recorded

Apr 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

I-Mab Biopharma US Limited
Merck Sharp & Dohme LLC

Data source: I-Mab Biopharma US Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Beijing, China , Birmingham, United States , Dalian, China , Detroit, United States , Guangzhou, China , Hangzhou, China , Jacksonville, United States , Lafayette, United States , Nashville, United States and 11 more locations